Net sales during the quarter increased by 34.2% year-on-year (YoY) to Rs 168.27 crore. On the segmental front, revenue from vaccines segment was at Rs 58.81 crore (up 86.7% YoY) while that from formulations segment was at Rs 109.46 crore (up 16.6% YoY) in the fourth quarter.

The company reported a pre-tax loss of Rs 52.65 crore in Q4 FY21 compared with the pre-tax loss of Rs 60.55 crore recorded in the same period last year.

Panacea Biotec recorded a consolidated net loss of Rs 147.65 crore in FY21 as against a net loss of Rs 194.29 crore in FY20. Net sales rose 14.8% year-on-year (YoY) to Rs 624.81 crore in FY21 over FY20.

The company's board has approved raising of funds through one or more permissible mechanisms as may be deemed appropriate by the board, for an amount up to and not exceeding Rs 1,200 crore or it is equivalent in any other currency(ies), in one or more tranches.

Panacea Biotec is an innovation-led biotechnology group that focuses on discovery, development, and commercialization of prescription medicines.